Skip to content

PET Imaging of Peripheral Benzodiazepine Receptors in Patients With Carotid Atherosclerosis

PET Imaging of Peripheral Benzodiazepine Receptors in Patients With Carotid Atherosclerosis

Status
Completed
Phases
Phase 1
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT00547976
Enrollment
5
Registered
2007-10-23
Start date
2007-10-31
Completion date
2009-08-31
Last updated
2012-04-27

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Atherosclerosis, Healthy

Keywords

Inflammation, Unstable Plaque, Macrophage, Thrombosis, Autoradiography, Atherosclerosis, Vasculitis

Brief summary

Inflammation in the vascular wall is important in atherosclerosis and the blockage of the artery. The peripheral benzodiazepine receptor is involved in inflammation and in this protocol we will attempt to take pictures, using PET camera, of inflammation in patients with atherosclerosis and compare those of healthy people.

Detailed description

Objective Inflammation in the vascular wall plays an important role in the pathophysiology of atherosclerosis, including development of plaque, plaque destabilization and rupture. Clinical and basic scientific data demonstrate the importance of peripheral white blood cells in this process. Therefore, a noninvasive method to detect inflammatory activity in atherosclerosis may be of great value to help determine prognosis, direct therapy and perhaps assess novel therapies for stabilization of atherosclerotic plaque. The peripheral benzodiazepine receptor (PBR) is distinct from central benzodiazepine receptors associated with GABAA receptors and has been associated with immune function. PBR is expressed in macrophages, therefore, they may be a clinically useful marker to detect inflammation. Our preliminary autoradiographic data demonstrate specific PBR binding in carotid atherosclerosis samples. Though PBR has been imaged in vivo with positron emission tomography (PET) using \[(11)C\]1-(2-chlorophenyl-N-methylpropyl)-3-isoquinoline carboxamide (PK11195), we developed a new ligand, \[(11)C\]N-acetyl-N-(2-methoxybenzyl)-2-phenoxy-5-pyridinamine (PBR28) that shows greater specific signal than \[(11)C\]PK11195 in non-human primates. The objective of this protocol is to assess the utility of \[(11)C\]PBR28 PET to detect inflammation in unstable atherosclerosis plaques and large vessels with inflammation. Study population Twenty patients with carotid atherosclerosis, 20 patients with large vessel vasculitis including Takayasu's and Giant Cell arteritis, and 20 age-matched healthy subjects will have one PET scan. Design A \[(11)C\]PBR28 PET scan and a \[18 F\] fluorodeoxyglucose (FDG) PET scan will be performed in patients with carotid atherosclerosis. If the patient has endarterectomy after the PET scan, endarterectomy samples will be evaluated by in vitro autoradiography using \[3H\]PK 11195 and immunohistological staining with macrophage markers. Patients with large vessel vasculitis and healthy subjects will also have a \[(11)C\]PBR28 PET scan \[18 F\]FDG PET scan. Outcome measures Binding of \[(11)C\]PBR28 in atherosclerotic lesions, aortic arch and its branches will be compared with the binding in the contralateral carotid artery and those in healthy subjects. Binding of \[(11)C\]PBR28 will also be compared with accumulation of \[18 F\]FDG in each region. In addition, if the patients with atherosclerosis have endarterectomy, the binding in the atherosclerotic lesions will be compared with immunohistological staining of macrophage markers.

Interventions

Sponsors

National Institute of Mental Health (NIMH)
Lead SponsorNIH

Study design

Allocation
NON_RANDOMIZED
Intervention model
PARALLEL
Primary purpose
DIAGNOSTIC
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
18 Years to 89 Years
Healthy volunteers
No

Inclusion criteria

* INCLUSION CRITERIA Age 18 - 89 Ability to provide written informed consent

Exclusion criteria

Severe systemic disease based on history, physical examination or laboratory tests that would prevent participation in the study Prior participation in other research protocols in the last year such that radiation exposure would exceed the annual guideline of RSC Pregnancy and breast feeding Claustrophobia Inability to lie flat for a few hours for the PET scans Medically unstable The blood glucose level is greater than 150 mg/dL after fasting Any other condition which in the opinion of the PI would prevent satisfactory participation in and completion of the study.

Design outcomes

Primary

MeasureTime frame
Binding of [11C]PBR28 at peripheral benzodiazepine receptor3 years

Secondary

MeasureTime frame
PET [F-18]FDG uptake3 years

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 23, 2026